NICE starts work on setting quality standards
The UK's National Institute for Health and Clinical Excellence (NICE) says it welcomes the referral of four clinical areas by the Department of Health following advice from the National Quality Board and will now begin work on setting NICE quality Standards for the NHS using a pilot process.
The Darzi report, High Quality Care For All (June 2008), Expanded the NICE's role to include setting and approving more independent quality standards for the NHS. The report highlighted the difficulties clinicians faced in keeping up
with the best evidence. It stated that standards should clarify what high quality care looks like with regard to:
- Clinical effectiveness
- Patient safety
- Patient experience
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze